Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01733992 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease
A Phase 1 study, sponsored by Rigel Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01733992 is a Phase 1 study that has completed, run by Rigel Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT01733992, a Phase 1 study, has completed, sponsored by Rigel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of R348 eye drops in patients with dry eye disease.
Interventions
- DRUG Placebo
- DRUG R348 Ophthalmic Solution, 0.2%
- DRUG R348 Ophthalmic Solution, 0.5%
- DRUG R348 Ophthalmic Solution, 1.0%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01733992
The ClinicalTrials.gov registry entry for NCT01733992 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01733992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01733992 about?
NCT01733992 is a clinical study titled "A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease". The purpose of this study is to determine the safety, tolerability and pharmacokinetics of R348 eye drops in patients with dry eye disease.
What is the current status of trial NCT01733992?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2012-11. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01733992?
The interventions under investigation include: Placebo (DRUG), R348 Ophthalmic Solution, 0.2% (DRUG), R348 Ophthalmic Solution, 0.5% (DRUG), R348 Ophthalmic Solution, 1.0% (DRUG).
Who is sponsoring clinical trial NCT01733992?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.